Fluoxetine Egis

Quick links

Choose a section

Quick links to important sections

Advertisements

Fluoxetine Egis

Advertisements
Advertisements

Overview of Fluoxetine Egis

Quick Facts

Property Description
Active Ingredient Fluoxetine hydrochloride
Form Capsules or tablets (oral)
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
Manufacturer Egis Pharmaceuticals
General Purpose Mood stabilization and anxiety reduction

What Type of Medicine is Fluoxetine Egis?

Fluoxetine Egis is a generic antidepressant medication that contains the active ingredient fluoxetine, which belongs to the pharmacological class known as Selective Serotonin Reuptake Inhibitors (SSRIs).

Fluoxetine is a well-established, synthetic compound used in therapeutic settings. The "Egis" designation identifies the manufacturer, a pharmaceutical company based in Central Eastern Europe, which distinguishes this particular version from other generic formulations of fluoxetine. As a generic drug, it is developed to have the same quality, effectiveness, and strength as the original innovator drug, providing a cost-effective option for patients.

What is the Purpose and Form of Fluoxetine Egis?

The overall purpose of fluoxetine is to help stabilize emotional balance and reduce the persistent feelings of anxiety and distress that affect daily life.

This is achieved by its selective influence on the brain’s serotonin system. The medication is typically available as an oral capsule or tablet, designed for daily use. The mechanism of fluoxetine involves delaying the reuptake of serotonin, causing the neurotransmitter to persist longer where it is released. This specific formulation is characterized by a long half-life compared to some other SSRIs, a property that helps maintain steady drug levels in the body.

Why is Fluoxetine a Selective Serotonin Reuptake Inhibitor (SSRI)?

Fluoxetine is designated as an SSRI because it acts in a highly targeted manner, focusing primarily on adjusting the levels of the neurotransmitter serotonin.

This selectivity is its defining characteristic within the antidepressant field. The intent of this targeted approach is a focused mechanism designed to promote gradual but sustained improvement in emotional well-being, helping the patient return to a more stable emotional baseline.

Regulatory References

  1. NIH Review
Advertisements

What side effects are possible with Fluoxetine Egis?

Possible Side Effects and Safety Information

The safety profile of Fluoxetine Egis, which contains fluoxetine, is classified based on incidence rates documented in official regulatory documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by the affected System-Organ Class and classified by frequency. Very common reactions (occurring in more than 1 in 10 individuals) typically include headache, insomnia, diarrhoea, and nausea. Common reactions (occurring in 1 in 100 to 1 in 10 individuals) include anxiety, dizziness, tremor, dry mouth, and decreased appetite.

Serious Safety Considerations

Official labels highlight the risk of certain serious adverse reactions. This includes a Black Box Warning regarding an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (under 25 years old), particularly during the start of treatment or following dose adjustments. Other documented serious risks include Serotonin Syndrome, serious allergic reactions (such as Stevens-Johnson syndrome), QT prolongation (a heart rhythm risk), and an increased potential for abnormal bleeding.

Population-Specific and Contextual Safety Notes

Regulatory documents detail safety considerations for specific groups. Patients with hepatic impairment may require dose modification due to the liver’s role in metabolizing the drug. Older adults may have an increased susceptibility to hyponatremia (low sodium levels). The drug's active substance has a long half-life, meaning it remains in the body for several weeks after the last dose, which is an important consideration when starting or stopping other treatments.

Advertisements

Overdose and Emergency Response

Suspected overdose with fluoxetine requires immediate medical attention, as directed by official prescribing information. The clinical presentation of an overdose is formally documented and may involve Central Nervous System (CNS) and cardiovascular manifestations.

Documented Manifestations

Overdose manifestations described in regulatory sources commonly include gastrointestinal effects such as nausea and vomiting, as well as neurological changes such as tremor, somnolence (drowsiness), and CNS excitation. More severe outcomes involve seizures and potentially life-threatening cardiovascular effects, including QT prolongation and ventricular arrhythmia, such as Torsades de Pointes. The risk of Serotonin Syndrome is also noted in the context of overdose, particularly when other serotonergic agents are involved.

Required Emergency Actions

Regulatory guidance mandates that you seek immediate medical attention for any suspected overdose. Due to the potential for serious complications, continuous monitoring of vital signs and cardiac rhythm is recommended. Management consists of general symptomatic and supportive measures. It is formally stated that no specific antidote is known for fluoxetine overdose. Because the long half-lives of fluoxetine and its active metabolite result in prolonged presence in the body, observation may be required for an extended period.

Advertisements

Therapeutic Uses of Fluoxetine Egis

Fluoxetine Egis is applied to support symptomatic relief across several key therapeutic domains, focusing on conditions where emotional balance, impulse control, and symptoms that interfere with daily functioning are significantly impaired. It is used when symptom clusters create noticeable interference with daily stability, providing support that helps ease the overall burden of distressing manifestations.

Fluoxetine is indicated for use across several core therapeutic domains involving both acute and chronic symptoms.

Relief for Depressive and Related Mood Symptoms

This medication is commonly used to address the pronounced symptoms of Major Depressive Disorder (MDD), which include persistent low mood, hopelessness, and the loss of interest or pleasure (anhedonia). It is also relevant for managing the severe, cyclical irritability and dysphoria associated with Premenstrual Dysphoric Disorder (PMDD). Applied in contexts where additional symptomatic support is needed, it contributes to improved day-to-day comfort and supports the maintenance of emotional stability.

Fluoxetine is commonly used to help with conditions presenting with acute episodes like Major Depressive Disorder, Obsessive-Compulsive Disorder (OCD), and Panic Disorder, as well as chronic challenges such as Bulimia Nervosa and cyclical distress associated with PMDD.

Management of Intrusive Anxiety and Obsessive Behaviors

Fluoxetine Egis is applied across domains where additional symptomatic support is needed for conditions involving heightened anxiety and compulsive patterns. It helps manage the intensity of intrusive, unwanted obsessive thoughts and the repetitive, ritualized compulsive acts. For panic, it is applied in addressing pronounced symptoms, and may assist with managing the frequency and severity of acute panic attacks.


Quick Fact: Symptomatic Support

Therapeutic Focus Symptom Context
Emotional Balance Used in situations involving persistent low mood and hopelessness
Anxiety Control Relevant for managing symptoms that interfere with daily comfort, such as panic attacks
Behavioral Patterns Applied when conditions produce significant symptomatic burden, such as binge-eating and purging

Regulatory References

  1. Fluoxetine capsule - DailyMed - NIH
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fluoxetine Egis — Official Regulatory Information


Eligibility Scope

Category Regulatory Status Details
Populations Contraindicated Absolute Prohibition Patients with known hypersensitivity to fluoxetine, and those concurrently taking Monoamine Oxidase Inhibitors (MAOIs), Pimozide, Thioridazine, Linezolid, or Intravenous Methylene Blue (prohibited co-administration).
Populations Allowed Approved Use Adults are approved for all labeled indications. Pediatric use is approved for Major Depressive Disorder (8 years) and Obsessive Compulsive Disorder (7 years).
Condition-Specific Rules Restricted/Conditional Use Patients with significant hepatic impairment require a lower or less frequent dose. Use must be cautious in patients with a history of seizures or conditions that potentially lower the seizure threshold, and in those with pre-existing cardiac conditions that predispose to QT prolongation.
Pregnancy and Lactation Not Recommended/Restricted Use during pregnancy is restricted, permitted only if the potential benefit justifies the potential risks. Breastfeeding is generally not recommended due to excretion into human milk.

Eligibility Classifications (High-Level)

Official eligibility statements:

  • The drug is contraindicated for use with an MAOI, requiring a washout period.
  • Use is approved for specific pediatric age groups based on the indication, but not approved for Bulimia Nervosa or Panic Disorder in children.
  • A lower or less frequent dose is required for patients with significant hepatic impairment.

Connection to the overall eligibility profile:

Regulatory documents strictly define who is eligible for the medicine based on absolute prohibitions (contraindications), concurrent medication restrictions, and physiological status. This framework also establishes specific age limits for approved use across different disorders and mandates conditional use for populations with impaired organ function or certain pre-existing conditions, such as cardiac issues or a history of seizures.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

It is crucial to inform your doctor or pharmacist of all medicines you are currently taking, have recently taken, or might take, including over-the-counter and herbal remedies. Combining Fluoxetine Egis with certain medications can lead to serious adverse effects, such as Serotonin Syndrome.

Medicines to AVOID with Fluoxetine Egis

The following medications should generally not be taken simultaneously with Fluoxetine Egis:

  • Monoamine Oxidase Inhibitors (MAOIs): Including phenelzine, tranylcypromine, and moclobemide. A period of at least two weeks must pass after stopping a non-selective MAOI before starting Fluoxetine Egis, and at least five weeks must pass after stopping Fluoxetine Egis before starting an MAOI.
  • Metoprolol used for heart failure.
  • Tamoxifen (used to treat breast cancer), as fluoxetine may reduce its effectiveness.
  • Pimozide or Mequitazine (antihistamines), due to the risk of serious heart rhythm disorders.

Caution is Required

Particular caution and close monitoring are necessary when Fluoxetine Egis is combined with the following, as dosage adjustments may be needed:

  • Medicines that affect the heart rhythm: Such as some antiarrhythmics, antipsychotics, and tricyclic antidepressants.
  • Medicines that lower the seizure threshold: Including tramadol and bupropion.
  • Other serotonergic drugs: Such as triptans, linezolid, St. John’s Wort, and other SSRIs or SNRIs, due to the increased risk of Serotonin Syndrome.
  • Warfarin or other anticoagulants, as fluoxetine may increase the risk of bleeding. Your doctor may need to perform extra blood tests to monitor your clotting time.
  • Alcohol consumption is generally advised against while taking Fluoxetine Egis.
Advertisements

Mechanism of Action

Targeted Serotonin Transporter Blockade

The drug's mechanism initiates with its selective inhibition of the Serotonin Transporter ( SERT) protein, which is primarily located on presynaptic nerve endings. By binding to SERT, fluoxetine prevents the active reabsorption of the neurotransmitter serotonin ( 5-HT) back into the neuron. This immediate molecular interaction increases the concentration and duration of 5-HT availability within the synaptic cleft, thereby enhancing the chemical signal for postsynaptic receptors. This focused molecular interaction serves as a primary initial step in the modulation of the central serotonergic system.

Neuroadaptive System Remodeling

The full physiological consequences are dependent on a slower, time-dependent neuroadaptive process, distinct from the initial SERT blockade. The chronic presence of high synaptic 5-HT concentration drives the subsequent desensitization and downregulation of inhibitory presynaptic autoreceptors. This complex cellular adaptation removes a physiological constraint on 5-HT release, resulting in a sustained increase in overall serotonergic signaling. This sustained modulation leads to structural changes, including the upregulation of Brain-Derived Neurotrophic Factor ( BDNF), which modulates the structure and function of neural circuitry involved in emotional processing.

Advertisements

Dosage and Administration Information

Fluoxetine Egis must be taken exactly as prescribed by your doctor. Dosage and duration of treatment vary depending on the condition being treated and individual patient factors, such as age and the presence of liver impairment. Do not alter your dose or stop treatment without first consulting your prescriber.

Administration Guidelines

Aspect Instruction
Timing Typically taken once a day, preferably in the morning. If taking more than 20 mg daily, your doctor may advise dividing the dose between morning and noon.
With Food Can be taken with or without food.
Consistency Try to take your medicine at the same time each day to maintain consistent levels in your body.
Formulations Fluoxetine is available in various forms, including capsules, tablets, and oral solution. Always follow the specific instructions for your prescribed form.

Response and Continuation of Treatment

Fluoxetine does not work immediately. It may take four to five weeks or longer before you experience the full benefits of the medication. It is crucial to continue taking the medication even if you feel well. Treatment for conditions like depression often requires continuation for at least 6 months after symptoms are resolved to prevent relapse.

Missed Dose

If you forget a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed one and take the next dose at the regular time. Do not take a double dose to make up for the forgotten one.

Do not stop taking Fluoxetine abruptly. Suddenly discontinuing the drug can lead to withdrawal symptoms (such as dizziness, anxiety, or sleep difficulty). Your doctor will need to reduce your dose gradually before stopping treatment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Exploring the Combination of Drug X and Drug Y

Research has explored the potential of combining drug X with drug Y for the study of severe chronic pain. This combination is under investigation as a research approach for individuals who have not found adequate relief from single-drug therapies.

The research conducted has included studies exploring potential interactions with physiological pathways. Some participants in the research reported a reduction in their discomfort. Early studies have evaluated the impact on quality of life for participants.


Phase 1 and Safety Data

The initial Phase 1 trials focused primarily on establishing dosage characteristics and characterizing the pharmacokinetics of the combined drugs.

  • Tolerance: The study reported that participants generally completed the treatment period without discontinuing due to adverse events.
  • Dosing: Studies evaluating this combination often initiated treatment with a low dose.
  • Adverse Effects: The most commonly reported side effects in the study included mild drowsiness, temporary nausea, and dry mouth. Studies indicate that participants consuming high-dose alcohol while on this medication reported increased adverse effects.

Phase 2 Investigations

Phase 2 investigations concentrated on assessing the early impact of the combination on reported pain levels in a larger group of participants.

  • Pain Reduction: Preliminary data indicated that a portion of participants reported a decrease in their pain intensity over the study period.
  • Onset of Effect: Phase 2 trials further examined the speed with which participants in the study reported a change in pain intensity across different treatment groups.
  • Comparative Analysis: Research continues to investigate the potential comparative effects of this combination for pain management.

Next Steps in Research

Ongoing Phase 3 trials are currently evaluating the long-term safety, benefit, and optimal dosage of the drug X and drug Y combination across diverse participant populations.

Key Studies & References

  1. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain - NICE Guideline NG193
  2. Opioids and antidepressants: which combinations to avoid - Australian Prescriber
  3. Effect of Combined Morphine and Duloxetine on Chronic Pain NCT03249558 (Example Phase 2/3 combination trial structure)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Fluoxetine Egis (FAQ)

Q: Is Fluoxetine Egis chemically the same as other fluoxetine brands like Prozac?

Fluoxetine Egis is a generic medicine that contains the same active ingredient, fluoxetine hydrochloride, as the original brand-name drug. Regulatory bodies establish that generic versions must be bioequivalent, meaning they are designed to work the same way in the body as the innovator drug.


Q: How long does fluoxetine stay in the body after the last dose?

According to the official product information, the active substance and its main metabolite have a very long half-life. The active substance may remain in the body for a considerable time, often up to several weeks after the last dose. This fact is noted as a relevant factor when planning to start or stop other treatments.


Q: Can a missed dose of Fluoxetine Egis cause any specific problems?

Regulatory information emphasizes the need for consistent dosing. Because the medicine works best at steady levels, missing a dose may lead to temporary fluctuations in drug levels. A return or worsening of symptoms of the underlying condition has been reported in these circumstances.


Q: What is the general advice regarding dosage changes for Fluoxetine Egis?

Official product information states that dosage adjustments are performed by a healthcare professional based on the individual patient's response and tolerability. Dosing for specific populations, such as those with liver impairment, may require reduced amounts or less frequent administration.


Q: Is weight gain a documented or frequent side effect of Fluoxetine Egis?

Official documents report decreased weight as a common side effect of fluoxetine. While weight gain is also noted as an adverse event, it is typically reported with a lower frequency than weight loss.


Q: Does Fluoxetine Egis have an effect on a person's sleep patterns?

Yes, official product documents indicate that fluoxetine can affect sleep patterns. Insomnia (difficulty sleeping) is listed as a very common side effect, while somnolence (drowsiness) and general sleep disorders are also common reactions.


Q: Is it normal to feel more anxious or restless when first starting the medication?

Anxiety, nervousness, and restlessness are documented as common side effects, typically occurring in 1 in 100 to 1 in 10 individuals. These effects, which are documented as common, are sometimes reported to be more noticeable when beginning treatment or following a dose adjustment.


Q: Does Fluoxetine Egis interact with common pain relievers like ibuprofen?

Regulatory warnings indicate caution is advised when co-administering fluoxetine with non-steroidal anti-inflammatory drugs (NSAIDs) suchus ibuprofen. The combination is associated with an increased risk of abnormal bleeding due to the medication's effect on blood clotting function.


Q: Is Fluoxetine Egis ever prescribed for children or adolescents?

Yes, official product information confirms that fluoxetine has approved pediatric uses based on clinical evidence. It is indicated for Major Depressive Disorder for patients 8 years old and Obsessive Compulsive Disorder for patients 7 years old.


Q: Are older adults more susceptible to certain side effects from Fluoxetine Egis?

Regulatory information notes that older adults may have an increased susceptibility to hyponatremia (low sodium levels in the blood). Official documents state caution is generally advised for this population, due to the possibility of age-related organ impairment.


Q: Is Fluoxetine Egis considered a 'first-line' treatment for depression?

Official drug labeling confirms its approval for treating Major Depressive Disorder. The designation of a drug as a 'first-line' treatment is a matter of clinical practice guidelines, which is a clinical classification beyond the scope of the regulatory drug label itself.


Q: What are the officially approved conditions that Fluoxetine Egis is used to treat?

Official regulatory documents indicate that Fluoxetine Egis is approved for several conditions in adults. These typically include Major Depressive Disorder, Obsessive Compulsive Disorder (OCD), Bulimia Nervosa, and Panic Disorder.


Q: What does the official documentation say about sexual side effects from Fluoxetine Egis?

Official documents report that decreased libido, erectile dysfunction, ejaculation failure, and orgasmic dysfunction are documented adverse reactions. Regulatory warnings also note the risk of sexual dysfunction that may persist after discontinuation, which is typically considered rare.


Q: What are the general signs of Serotonin Syndrome and its connection to Fluoxetine Egis?

Serotonin Syndrome is described in official warnings as a potentially serious reaction characterized by a group of signs. These can include changes in mental status (e.g., agitation, hallucinations), autonomic instability (e.g., rapid heart rate), and neuromuscular changes (e.g., tremors, rigidity).


Q: What classes of cold and flu medicines should be checked for interaction with Fluoxetine Egis?

Regulatory information indicates caution with over-the-counter medicines containing serotonin-affecting agents. This includes certain cough suppressants like dextromethorphan or decongestants like sympathomimetic agents due to the potential for Serotonin Syndrome or cardiovascular effects.


Q: Are there any specific foods or beverages that should be avoided?

Official product information states that consuming alcohol while using this medicine is generally advised against. No specific food restrictions (such as those for tyramine) are usually noted in the official labeling for fluoxetine.


Q: Is there research evidence for the use of Fluoxetine Egis in treating conditions other than depression?

The drug's official approval is based on clinical evidence showing effectiveness for several conditions, beyond depression. Approved indications like Bulimia Nervosa and Obsessive Compulsive Disorder (OCD) are based on research submitted to regulatory bodies.


Q: Is Fluoxetine Egis considered habit-forming or addictive?

Fluoxetine is not classified as a controlled substance by regulatory bodies and is not generally associated with addictive properties. However, official documents describe the potential for transient discontinuation symptoms if treatment is stopped abruptly.


Q: Why do some users report feeling 'emotionally numb' on fluoxetine?

Official documentation reports adverse reactions related to emotional state, such as apathy or decreased emotional range. These documented emotional changes may correlate with what users commonly describe as 'emotional numbness.'


Q: Does Fluoxetine Egis carry any warnings about driving or operating machinery?

Official warnings indicate that caution should be exercised because the drug may impair the ability to perform skilled tasks, such as driving or operating complex machinery. This is due to potential common side effects like dizziness or drowsiness.


Q: Is Fluoxetine Egis known to cause excessive sweating?

Hyperhidrosis, the medical term for excessive sweating, is documented as a common side effect of fluoxetine. It is reported to occur in 1 in 100 to 1 in 10 individuals using the medication.


Q: What is the official information regarding hair loss and Fluoxetine Egis?

Alopecia, or hair loss, is documented as an adverse reaction in the official product information. This is typically reported as a less common event.


Q: Why is Fluoxetine Egis sometimes prescribed for premenstrual dysphoric disorder (PMDD)?

The drug is specifically approved and indicated for the treatment of Premenstrual Dysphoric Disorder (PMDD). This approval is based on clinical evidence demonstrating its effectiveness for the condition.


Q: What is the official definition of 'discontinuation syndrome' related to Fluoxetine Egis?

The official term Discontinuation Syndrome refers to the transient adverse reactions that may occur upon cessation or reduction of the drug. Symptoms described in regulatory documents include dizziness, sensory disturbances, and anxiety.


Q: Does Fluoxetine Egis affect blood pressure?

Official documents report that both Hypotension (low blood pressure) and Hypertension (high blood pressure) are documented as adverse reactions associated with the medication.


Q: Is it necessary to inform a dentist or surgeon about using Fluoxetine Egis?

Official warnings regarding the increased risk of abnormal bleeding indicate that it is important that all healthcare providers be informed of current medication use. This notification includes dentists or surgeons before any procedure.


Q: Does Fluoxetine Egis affect cholesterol levels?

Official documents note that changes in cholesterol levels have been reported as an uncommon adverse reaction to the medication. This is based on clinical data collected during research and monitoring.


Q: Why is there a warning about using Fluoxetine Egis in patients with glaucoma?

Regulatory warnings indicate that caution is advised when the drug is administered to patients with narrow-angle glaucoma or a history of it. This is due to a documented risk of pupillary dilation which could potentially trigger an acute attack of the condition.


Q: What is the purpose of the different strengths of Fluoxetine Egis available?

Different strengths are made available to allow for individualized dose titration by the prescribing physician. This process is necessary to achieve the desired effect while helping to minimize adverse reactions for the individual patient.


Q: Does Fluoxetine Egis have a known effect on blood sugar levels?

Changes in blood sugar levels, including cases of both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar), have been reported in official documents. Due to this possibility, careful monitoring is relevant for patients with diabetes.

Advertisements

How should Fluoxetine Egis be stored and disposed of?

Official Storage and Disposal Requirements

Fluoxetine Egis must be stored and disposed of strictly according to regulatory guidelines to ensure stability and safety.

Storage Category Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection Keep in the original container, tightly closed, protected from moisture and light.
Child Safety Store out of the sight and reach of children and ensure safety caps are locked.
Stability Do not use after the expiry date. The oral solution must be discarded 60 days after first opening.

For disposal, the medicine must not be thrown away via wastewater or household waste. The recommended method is to use a drug take-back program. If this is unavailable, mix the unused product with an unappealing substance, place it in a sealed bag, and discard it in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluoxetine Egis found in:

A-Z Index: